Dihydrofolate reductase (DHFR) is a pivotal enzyme involved in the de novo pathway of purine synthesis, and hence, represents an attractive target to disrupt systems that require rapid DNA turnover. The enzyme acquires resistance to available drugs by various molecular mechanisms, which necessitates the continuous discovery of novel antifolates. Previously, we identified a set of novel molecules that showed binding to E. coli DHFR by means of a thermal shift without establishing whether they inhibited the enzyme. Here, we show that a fraction of those molecules represent potent and novel inhibitors of DHFR activity. 7-[(4-aminophenyl) methyl]-7H-pyrrolo [3,2-f] quinazoline-1,3-diamine, a molecule with no reported inhibition of DHFR, potently inhibits the enzyme with a K i value of 7.42 AE 0.92 nM by competitive displacement of the substrate dihydrofolic acid. It shows uncompetitive inhibition vis-a-vis NADPH, indicating that the inhibitor has markedly increased affinity for the NADPH-bound form of the enzyme. Further, we demonstrate that the mode of binding of the inhibitor to the enzyme-NADPH binary complex conforms to the slow-onset, tight-binding model. By contrast, mechanistic characterization of the parent molecule 7H-pyrrolo [3,2-f] quinazoline-1,3-diamine shows that lack of (4-aminophenyl)-methyl group at the seventh position abolishes the slow onset of inhibition. This finding provides novel insights into the role of substitutions on inhibitors of E. coli DHFR and represents the first detailed kinetic investigation of a novel diaminopyrroloquinazoline derivative on a prokaryotic DHFR. Furthermore, marked differences in the potency of inhibition for E. coli and human DHFR makes this molecule a promising candidate for development as an antibiotic.
Introduction
Dihydrofolate reductase (DHFR, EC 1.5.1.3) is a ubiquitous enzyme found in all kingdoms of life. The enzyme is involved in the reduction of 7,8-dihydrofolate (H 2 F) to 5,6,7,8-tetrahydrofolate (H 4 F) during which protonation of H 2 F on N5 precedes the hydride transfer from C4 of the NADPH cofactor to the C6 atom of the pterin ring on H 2 F [1] . Since DHFR is the sole source of cellular tetrahydrofolate, a metabolite essential for thymidylate and purine synthesis, its activity is indispensable. Thus, the enzyme represents an attractive target to disrupt systems that require rapid DNA turnover, e.g. proliferating cancer cells and pathogenic microbes [2] . Escherichia coli DHFR has been extensively characterized in terms of kinetic mechanism, catalysis and structural studies [3] [4] [5] [6] . This wealth of data makes the enzyme an attractive target for the design of small-molecule inhibitors as potential antibiotics. This has become all the more important given the increase in instances of nosocomial infection caused by drug-resistant E. coli [7] . However, designing inhibitors for DHFR presents considerable challenges because the enzyme acquires rapid resistance to available drugs by means of gene amplification, mutations and decreased drug uptake [8] .
A lot of effort has been expended on discovering novel inhibitors for DHFR from different organisms, given their potential applications to antineoplastic, anti-inflammatory and anti-infective drug discovery [9] [10] [11] . Methotrexate (MTX), a 2,4-diaminopteridin, is by far the most well characterized inhibitor of DHFR, showing a slightly increased potency of inhibition for parasitic DHFR compared to either human or bacterial DHFR. Other prominent antifolates include the pyrimidine-2,4-diamine pyrimethamine, which is highly specific for eukaryotic DHFRs, trimethoprim, which shows a slightly greater preference for prokaryotic DHFRs [2] , metoprine and piritrexim. Further, to overcome the limitation imposed by the hydrophilic nature of MTX, which hinders its distribution across different tissues, lipophilic inhibitors like trimetrexate, a quinazoline-2,4-diamine, have been synthesized as nonclassical inhibitors of DHFRs. Pyrrolo [3,2-f] quinazoline-1,3-diamine derivatives, containing a novel tricyclic heterocycle compared with trimetrexate, were further explored and shown to be inhibitors of parasitic DHFRs [12] . Other studies have shown 7,8-dialkyl-1,3-diaminopyrrolo [3,2-f] quinazoline compounds to be high-affinity inhibitors of DHFR from Pneumocystis carinii and Candida albicans [13] . In yet another study, a high-throughput screen identified 12 compounds as inhibitors of E. coli DHFR [14] . However, it should be noted that detailed kinetic studies on the inhibition brought about by these novel DHFR inhibitors is lacking.
Previously, as part of experimental validation of the virtual ligand-screening algorithm FINDSITE comb and relying on thermal-shift assay methodology, we reported a set of novel molecules that showed binding to E. coli DHFR [15, 16] . Here, employing inhibition kinetics, we show that a fraction of those molecules represent novel inhibitors of DHFR activity and present detailed mechanistic characterization to substantiate our claims. By means of extensive steadystate and tight inhibition kinetics studies, we show for the first time that 7-[(4-aminophenyl) methyl]-7H-pyrrolo [3,2-f] quinazoline-1,3-diamine (AMPQD) and its parent compound, 7H-pyrrolo [3,2-f] quinazoline-1,3-diamine (PQD), are novel tight-binding inhibitors of E. coli DHFR. These inhibitors preferentially bind to the NADPH-bound form of the enzyme at the H 2 Fbinding site. Although AMPQD shows slow onset of binding to the enzyme, PQD shows no such behavior, implicating the (4-aminophenyl) methyl group as a possible origin of the slow binding behavior in E. coli DHFR. This, combined with our already reported antibacterial, antifungal and antineoplastic activity by these compounds against two different strains of E. coli (multidrug-resistant E. coli and DH5a), a strain of methicillin-resistant Staphylococcus aureus, a strain of vancomycin-resistant Enterococcus faecalis, a strain of amphotericin B-resistant C. albicans and HCT-116 human colon carcinoma cell line, makes these compounds potential lead candidates to target conditions arising from aberrant DHFR activity [15] . Further, pronounced differences in the potency of inhibition and the mode of inhibitor binding for AMPQD and PQD against E. coli and human DHFR make these molecules attractive candidates for development as novel antibiotics.
Results

Inhibition of E. coli DHFR
All the hits from the FINDSITE comb experimental validation study were assessed for their ability to inhibit E. coli DHFR. The histogram in Fig. 1 summarizes the results. All the reported inhibitors of DHFR from various sources, viz. MTX (NSC740), PQD (NSC 339578), methylbenzoprim (NSC382035), pralatrexate (NSC754230), pemetrexed (NSC698037) and 6,7-bis(4-aminophenyl) pteridine-2,4-diamine (NSC61642), show unambiguous inhibition of E. coli DHFR at a 1 mM inhibitor concentration. Prior to carrying out IC 50 determination and detailed inhibition studies, the kinetic parameters for the substrate H 2 F and cofactor NADPH were determined and found to be in agreement with values reported in the literature within experimental error (Table S1 and Fig. S1 ) [17, 18] . For all further experiments, except when a substrate is titrated, the substrates were kept at > 10 times their respective K m values. Table 1 and Fig. S2(A,B) summarize the IC 50 values, defined as the concentration of inhibitor required to reduce the activity of the enzyme by 50%, determined for a select set of reported inhibitors of E. coli DHFR independently identified by our studies.
Among the nine novel binders reported previously, seven were tested for their inhibition of E. coli DHFR [15] . Three (NSC309401, NSC80735 and NSC55152) showed almost complete inhibition and one molecule (NSC123458) showed~87% inhibition at a 1 mM inhibitor concentration (Fig. 1) . While NSC309401 (AMPQD) is a substrate analogue with the quinazoline-1,3-diamine group, NSC80735 and NSC55152 contain concatenated nitrophenyl and aminophenyl groups. To further understand their inhibition, IC 50 values were determined for the various molecules. Figure 2A shows the curve of log inhibitor concentration versus activity for AMPQD, giving an IC 50 value of 189.0 AE 1.0 nM (Table 1) . This indicates potent inhibition comparable to that shown by MTX, with an IC 50 value of 152.5 AE 1.1 nM. However, since it is known from the literature that IC 50 values are enzyme concentration dependent and can never be < [E 0 ]/2 [19] , it is highly likely that the number represents an underestimation of the actual affinity of the inhibitor for the enzyme (Fig. 2B) . To account for this tight binding inhibition, the data were analyzed as per the methods developed by Morrison and coworkers [20, 21] . Figure 2C shows the fit of the data to the quadratic Morrison equation for tight binding and Table 1 [15] . Detailed mechanistic characterization was undertaken on AMPQD (the best hit from the FINDSITE comb study), PQD (the parent molecule of AMPQD) and MTX (a well characterized DHFR inhibitor) to understand their mode of inhibition (Fig. 3) .
AMPQD (NSC309401) is a competitive inhibitor of dihydrofolate binding
To further understand the inhibition shown by AMP-QD, we resorted to detailed inhibition kinetics. Substrate dihydrofolate was titrated at several fixed On the plots, the y-axis represents % activity of the enzyme and the x-axis represents the log inhibitor concentration/inhibitor concentration. The experimental data points were fitted to the respective equations using the nonlinear curve-fitting algorithm of GraphPad PRISM v. 6.0e.
concentrations of AMPQD, and the resulting curves from the primary plot, when globally fit to models for the various types of inhibition, showed the best fit to the model for competitive inhibition (see Experimental Procedures for details) (Fig. 4A) yielding a K i , the equilibrium dissociation constant for the competitive inhibitor, of 7.42 AE 0.92 nM (Table 2) . Further, for visual assessment, the data were transformed and plotted as the double-reciprocal Lineweaver-Burk plot. Figure 4B shows the lines of the Lineweaver-Burk plot intersecting on the y-axis, which is further indicative of competitive displacement of substrate dihydrofolate by AMPQD, whereby it increases the apparent K m value for the substrate without unduly affecting the V max . Further, this low K i value, similar to that obtained from fitting to the Morrison equation, reinforces the fact that AMPQD is a tight-binding inhibitor, a special case in which the affinity of the inhibitor for the enzyme is an order-of-magnitude lower than the minimum concentration of enzyme that can be employed in the assay mix to obtain reliable activity. Further, the K i value is~25-fold lower than the obtained IC 50 . However, the K i value for AMPQD is approximately twofold higher than that reported for MTX (the reported value is~3.6 nM) [22] . The above data are conclusive about AMPDQ binding to the same site as dihydrofolate and competing with the latter for highaffinity interactions with the enzyme. This competitive displacement can be ascribed to the quinazoline-1,3-diamine group shared by the two molecules (substrate and inhibitor), which might serve as the common motif responsible for binding. Although this behavior is similar to that shown by MTX, it is markedly different from that of a pyrimidine-2,4-diamine pyrimethamine against Plasmodium DHFR, which is a noncompetitive inhibitor of the latter [23] .
AMPQD (NSC309401) is an uncompetitive inhibitor of NADPH binding
To understand the effect of AMPQD on the cofactor NADPH binding, the latter was titrated at several fixed concentrations of AMPQD, and the resulting curves from the primary plot, when globally fit to models for the various types of inhibition, showed the best fit to the model for uncompetitive inhibition ( Fig. 4C ) yielding an aK i , the equilibrium dissociation constant for the uncompetitive inhibitor, of 162.9 AE 9.1 nM ( Table 2) . This higher aK i value shows that the AMPQD binding site is fully formed only when the enzyme is bound to NADPH. It is worthwhile to point out that AMPQD K i was~7.4 nM at saturating NADPH (see above). Further, for visual assessment, the resulting data were transformed and plotted as the double-reciprocal Lineweaver-Burk plot. Figure 4D shows parallel lines on the LineweaverBurk plot, confirming the fit of primary data to model for uncompetitive inhibition. Data on the competition of AMPQD with NADPH are strongly indicative of an ordered binding event, whereby NADPH binding facilitates inhibitor binding. It should be noted that this pattern of uncompetitive inhibition against NADPH is similar to the way MTX behaves (Fig.  S3A ,B). Although, in principle, E. coli DHFR can bind to both NADPH and H 2 F randomly, as shown by some studies [6] , productive catalysis proceeds through ordered ternary complex formation with NADPH binding prior to dihydrofolate. Furthermore, the pattern is also consistent with the pH-independent and pH-dependent models of the E. coli DHFR kinetic mechanism proposed by Fierke et al. [4] , which show that dihydrofolate always binds to the NADPH-bound form of the enzyme. In a previous study, we have shown that AMPQD independently binds to the enzyme in the absence of NADPH [15] . Hence, the type of inhibition should ideally be either noncompetitive or linear mixed-type. However, the difference between K i and aK i is large. Hence, for all practical purposes, this inhibition can be considered uncompetitive. Thermal-shift assay measurements carried out from 0 to 500 nM AMPQD in the absence of NADPH were unsuccessful in stabilizing the protein and showed preferential binding to the denatured form of the protein. However, at a high concentration of 1 mM, the inhibitor showed binding to the enzyme, even in the absence of added NADPH, as seen in the thermal stability profile (Fig. S4 ). This further proves that AMP-QD binding in the nM concentration range is absolutely conditional upon NADPH binding to the enzyme.
PQD inhibition kinetics
PQD has been shown to possess inhibitory activity against DHFRs from eukaryotic sources, inhibiting fungal DHFRs [13] . In order to assess its inhibition of a prokaryotic enzyme, it was tested against E. coli DHFR ( Fig. 1 and Fig. S2A ). PQD is the parent molecule for AMPQD and lacks the latter's (4-aminophenyl) methyl group. Figure 5A ,B shows the primary curves for H 2 F titration at several different concentrations of PQD fit to the model of competitive inhibition and the double-reciprocal Lineweaver-Burk plot. Further, Fig. 5C ,D shows the primary curves for NADPH titration at several different concentrations of PQD fit to the model for uncompetitive inhibition and the double reciprocal Lineweaver-Burk plot. These patterns show that PQD occupies the H 2 F binding site and preferentially binds to the NADPH-bound form of the enzyme, mirroring the behavior shown by its derivative AMPQD. However, the K i value of 3.18 AE 0.51 nM for PQD is approximately half of that shown by AMPQD, indicative of tighter binding (Table 2) .
In an attempt to rationalize the ordered binding behavior, whereby all three inhibitors preferentially bind to the NADPH-bound binary complex of the enzyme, structures of E. coli DHFR in complex with NADPH (PDB ID: 1RX1) and MTX (PDB ID: 3DRC) were analyzed. When the structures were superimposed with their respective ligands, maximum change was noticed in the M20 loop that covers the active site where the hydride transfer reaction from NADPH to H 2 F happens (Fig. 6A) . Furthermore, it became clear that the dramatic change in the orientation of M20 from the MTX-bound form to NADPHbound form of the enzyme might be the principal reason of why the inhibitors prefer the NADPH form (Fig. 6A,B) . This shift in the orientation between the two structures makes the thio group of methionine come within hydrogen-bonding distance of the N8 group on MTX in the NADPH-bound structure. Since AMPQD shares this substructure with MTX, it is highly likely that this interaction with M20 increases the affinity of the inhibitor for the enzyme manifold. Further, apart from this principal interaction, the whole M20 loop with several charged and bulky residues undergoes a change between the two structures. Other residues that may have possible roles in this preferential binding of inhibitor to NADPH-bound form are M16 and E17.
Slow-onset tight-binding inhibition: comparative study between AMPQD and PQD AMPQD and PQD bind to E. coli DHFR with the same kinetic behavior as the well-characterized inhibitor MTX. Both are competitive with respect to H 2 F and show preferential binding to the NADPH-bound form. Since it is known that MTX shows a slow-onset tight-binding mode to the enzyme [22] , we wanted to ascertain whether this also holds true for AMPQD and PQD. The K iapp values obtained for both AMP-QD and PQD using steady-state methods show that the inhibitors are tight-binding inhibitors (Table 1) . Progress curve analysis was used to determine whether Table 2 . Parameters from inhibition kinetics and time-dependent inactivation of E. coli DHFR.
Inhibitors
Substrate the inhibitors showed slow-onset of tight binding in inhibiting E. coli DHFR. Upon addition of AMPQD, the rate of product formation decreased exponentially with time from an initial velocity (v i ) to a steady-state velocity (v s ) (Fig. 7A ). In addition, v i , v s and the time required to reach v s decreased with increasing concentrations of the inhibitor, whereas k obs increased (Fig. 7A inset) . This nonlinear behavior in product formation in the presence of inhibitor complies with both the simple reversible slow-onset tight-binding The experimental data points were fit to the respective models using the nonlinear curve-fitting algorithm of GraphPad PRISM v. 6.0e.
inhibition model and inhibitor binding followed by isomerization model. However, upon assessing the effect of preincubation time with inhibitor on the steady-state velocity of the reaction, whereby v/v i was plotted against time at various fixed inhibitor concentrations, the behavior conformed to the classic reversible slow-onset inhibition in which no isomerization happens after rapid formation of the initial E-I complex (data not shown). A simple reversible equilibrium between the enzyme and inhibitor with association and dissociation rate constants k 3 and k À3 , respectively, defines this model aptly, as shown in Scheme 1. This behavior is similar to that of any reversible inhibitor, except that the values of k 3 and/or k -3 are smaller, leading to the slow-onset of inhibition. Further, as can be seen in the inset to Fig. 7A , the increase in k obs is linear with respect to inhibitor concentration, conforming to the mechanism of reversible slow binding with slope equal to k 3 and y-intercept equal to k -3 . However, it should be noted that the measured value of k 3 is apparent, because this rate constant is substrate concentration dependent, as is seen in the plot of v i versus AMPQD at several fixed concentrations of H 2 F (Fig. 7B) . Hence, the apparent value of K i (K iapp ) for an inhibitor of this type can be calculated from the ratio of k -3 /k 3app , which is equivalent to the ratio of the y-intercept/slope from the linear fit of the data plotted as in Fig. 7 (A inset). The above analysis unequivocally proves that inhibition by AMPQD conforms to the classical slow-onset tight-binding reversible inhibition.
When the time-dependent inhibition data for PQD were analyzed, it was clear that the inhibition can be merely classified as classical tight-binding reversible inhibition because the curves show no hint of biphasic nonlinearity even at high inhibitor concentrations (Fig. 7C) . Because PQD is the parent molecule of AMPQD, the slow-onset behavior of the latter compound implicates 4-aminophenyl methyl substitution at the seventh position. It should also be noted that, unlike the inhibition mode of PQD, AMPQD inhibition of the enzyme is similar to that shown by MTX (Fig. 7D) . However, the physical basis for the slowonset behavior of both AMPQD and MTX in DHFRs remains unexplained, and we propose that substitutions on the 7H-pyrrolo [3,2-f] quinazoline-1,3-diamine for AMPQD and 2,4-diaminopteridin on MTX might be the principal determinant of the slow-onset behavior.
Differential inhibition of human and E. coli DHFR Escherichia coli and human DHFR share 28% sequence identity and are structurally highly conserved (Fig. S5) . It is well demonstrated that inhibitors designed against prokaryotic DHFRs inhibit the activity of DHFRs from eukaryotic sources, given the high sequence and structural similarity of this protein across different evolutionary lineages [2] . There are several examples of such broad inhibition with the most prominent example being the commonly employed antifolate MTX, which is known to inhibit DHFRs from E. coli, rat and Plasmodium species [2] . However, differences in potency and mode of inhibition, and the fact that antifolates target only rapidly proliferating cells like pathogenic microbes and tumors enable selective employment of them for specific treatment goals. With this aim, the hits obtained from the FINDSITE comb study [15] were assessed for their inhibitory activity on human DHFR. Figure 1 shows the comparative histogram of inhibition, demonstrating that both human and E. coli DHFR are inhibited to similar extent by various inhibitors at 1 mM inhibitor concentration. To understand the inhibition further, the IC 50 values for the various molecules were estimated (Table 1 and Figs 2A, S2) . Marked differences in the potency of AMPQD and PQD were seen in their inhibition of the homologous proteins from humans and E. coli. AMPQD, the novel hit from our study, showed an IC 50 of 599.0 AE 7.2 nM for the human DHFR, which is approximately threefold less potent than the IC 50 for E. coli DHFR ( Fig. 2A and Table 1 ). The most dramatic difference was PQD's inhibition of human DHFR with an IC 50 value of 3.09 AE 0.17 lM, representing a 30-fold reduction in the . The solid curves represent the best fit of the data to Eqn (7) for slow binding inhibition using GraphPad PRISM v. 6.0e.
potency of inhibition vis-a-vis E. coli DHFR (Fig. S2A and Table 1 ). However, the IC 50 values for inhibition of human and E. coli DHFR by MTX were comparable, with a value of~148 nM for the former and~152 nM for the latter. For the remaining molecules, the parameters are summarized in Table 1 and Fig. S2(B,C) . In order to further assess the effect of AMPQD on the human enzyme, competition experiments were performed by titrating H 2 F at several fixed concentrations of AMPQD. The curves thus obtained were fit to various inhibition models with the best fit obtained for competitive inhibition (Fig. 8A) . Further, the doublereciprocal Lineweaver-Burk plot shows intersection of the lines on the y-axis, reinforcing the competitive inhibition (Fig. 8B) . This indicates that AMPQD inhibits the human enzyme by competitive displacement of substrate H 2 F, similar to its mode of action against the E. coli enzyme. However, the K i value of 22.47 AE 3.66 nM for the human enzyme is almost threefold higher than that obtained for the E. coli enzyme (7.4 nM), indicative of poorer inhibition of the former.
Furthermore, upon analyzing the time dependence of NADPH depletion in the presence of AMPQD for the human enzyme, no nonlinearity was evident. This is indicative of neither slow onset nor slow dissociation of the inhibitor molecule to the human enzyme (Fig. S6A) . This is unlike the behavior displayed by the inhibitor AMPQD on the E. coli enzyme where prominent nonlinearity was evident from the time- course of NADPH depletion in the presence of the inhibitor (Fig. 7A) . Likewise, PQD also did not show any slow-onset of inhibition on the human enzyme, exactly mirroring its behavior on E. coli DHFR (Fig. S6B and 7B ). The differences in the mode of inhibition by AMPQD of the human and E. coli enzyme are strongly indicative of differences in the binding site microenvironment between the two homologs. In fact, a study by Bhabha et al. [24] has shown that, despite high structural similarity, the dynamics of the active site loop movements varies substantially between human and E. coli DHFR. This, they hypothesize, results in markedly different inhibition by the product NADP + of the two homologs (IC 50 of 620 lM for human DHFR versus~5 mM for E. coli DHFR). However, inhibition of human DHFR by the known antifolate MTX shows signs of pronounced nonlinearity in the time-course curves of NADPH consumption, indicating that the inhibitor retains its slowonset behavior as seen with E. coli DHFR (Fig. S6C) . Moreover, the plot of k obs versus MTX concentration is hyperbolic, indicative of isomerization after inhibitor binding (Fig. S6D) . This is yet another behavior seen in the inhibition of the human enzyme that is markedly different from that shown for its E. coli counterpart whereby, in the case of the latter, there was no isomerization whatsoever as seen in the linear k obs versus [MTX] plot for the inhibitor concentrations tested. (insets of Fig. 7D ).
Discussion
Because DHFR is a pivotal enzyme in the synthesis of precursors of DNA, it has been the target for both anticancer and antibacterial drugs [2] . There has been a plethora of folate analogues that have been synthesized and tested for potential inhibitory activity against DHFRs from various sources [2, 25] . Principal among these are MTX, used prevalently as an anticancer drug, and trimethoprim, used as an antibacterial drug. In spite of multiple inhibitors designed against DHFRs from various organisms, detailed mechanistic characterization is available for only a few of these molecules. However, detailed kinetic characterization of an inhibitor is essential for designing efficient inhibitors with greater potency against the intended target, determining the proper dose for testing on cellular/animal disease models and understanding the pharmacodynamics. Further, because DHFR acquires rapid resistance to newly discovered antifolates, it is necessary to keep discovering novel small molecules that inhibit this enzyme, especially given the rise in instances of nosocomial E. coli infections in hospitalized patients. Several reports in the literature highlight the fact that the incidence of E. coli-mediated infections in hospitalized patients is on the rise, with one study showing multidrug-resistant E. coli as the causative agent of urinary tract infection responsible for 40-50% of total nosocomial infections [7, 26, 27, 28] . Our study shows that AMPQD, a novel 7H-pyrrolo [3,2-f] quinazoline-1,3-diamine, is a potent inhibitor of the bacterial enzyme. Further, it also shows that compounds NSC80735, NSC55152 and NSC123458 show reasonable inhibition, with lM IC 50 values, and represent scaffolds amenable to modifications for the development of novel DHFR inhibitors. Whereas NSC80735 and NSC55152 contain concatenated nitrophenyl and aminophenyl groups, NSC123458 is a dibenzazepine that is a common structural scaffold in many antidepressants and analgesics.
In the current study, detailed steady-state inhibition experiments on E. coli DHFR have shown that the small molecules AMPQD and PQD bind to the H 2 Fbinding site and prefer the NADPH-bound binary form of the enzyme. This hints at sequential binding of the substrates NADPH followed by H 2 F, given that the small molecules are structural analogues of H 2 F. This order of substrate and substrate analogue binding is in conformity with those proposed in the literature [4] . Further, it is well documented in the literature that NADPH exerts a synergistic effect on folate analogues binding to DHFR. NADPH enhances the binding of all the classical (phenyltriazine, DADMP) and slowbinding (MTX, trimethoprim) inhibitors of DHFR, although it has no effect on either pyrimethamine or folate binding to DHFR. It has been reported that the degree of NADPH synergism can vary as much as 1000-fold for the binding among the different folate analogues [29] . We posit that because NADP and NADPH are present in equal concentrations in the prokaryotic cytosol (as opposed to the eukaryotic cytosol where NADP is no more than 1% of the concentration of NADPH) [30] , for an inhibitor to be an effective drug, it might be advantageous for it to inhibit the product-forming ternary form of the enzyme. Hence, inhibitors showing greater synergy may be preferable as potential lead candidates.
Tight-binding inhibitors are an important class in which the affinity of the inhibitor for its cognate enzyme is so high that the equilibrium assumptions employed to compute the affinity of the inhibitor for the enzyme no longer remain valid. Further, a lot of well-known inhibitors extensively employed as drugs also display the property of slow-onset of inhibition because of the time-dependent establishment of equilibrium between the enzyme-bound form and free inhibitor. A few examples are captopril [31] , an angiotensin inhibitor, Dup697 [32] , a COX2 inhibitor, and MTX [22, 33] , a DHFR inhibitor. MTX inhibits DHFR in a time-dependent manner involving the rapid formation of an enzyme-NADPH-MTX complex that undergoes relatively slow, reversible isomerization to form a thermodynamically stable ternary enzyme complex resulting in enhanced inhibition. Hence, the MTX concentration required for inhibition is comparable with the enzyme concentration employed in steady-state kinetic studies. This type of inhibition is categorized as slow-on/slow-off tight-binding inhibition [22] . Other folate analogues that exhibit slow-onset, tight-binding inhibition are 5-deazamethotrexate, aminopterin and trimethoprim, although the extent to which they bring about isomerization for slow dissociation differs significantly. Here, we demonstrate that AMPQD shows a slow-onset tight-binding behavior similar to that shown by MTX. However, upon analyzing the time-dependent inhibition curves, it becomes obvious that there is no pronounced isomerization, if any, which could be detected in the concentration range of inhibitor assessed. Mainly, the k obs versus inhibitor plots were linear both for AMPQD and MTX (Fig. 7A,D) even at high inhibitor concentrations. Further, we could convincingly rule out the possibility that there is isomerization of the enzyme between two different forms with the inhibitor preferably binding to one form by the fact that k obs increased (rather than decreased) with increasing inhibitor. For DHFR from E. coli, it has been reported that all folate analogues that act as tight binding inhibitors exhibit slow binding characteristics. However, slowonset does occur without tight binding as observed with 5-deazafolate. To the best of our knowledge, for the first time, we show that PQD is a tight-binding inhibitor of DHFR not displaying any slow-binding behavior, as is evident from the linear time-course curves (Fig. 7B) .
Further, pronounced differences in the potency of inhibition of AMPQD and PQD for the human and E. coli homologue, with an order-of-magnitude higher affinity for the latter, makes these molecules good candidates for development as effective antibiotics. It has been shown in the literature that recombinantly expressed human DHFR cannot complement DHFRdeficient E. coli cells, and this was ascribed to differences in the dynamics and conformational plasticity of the active site loops across the two different DHFRs [24] . This conjecture is further validated by our studies showing similar site of binding on both human and E. coli DHFR for the inhibitor AMPQD (H 2 F-binding site) (see Figs 4A and 8A) albeit with different modes (slow-onset tight binding for the E. coli enzyme, but merely tight binding for the human homologue as in Figs 7A and S6A) . Further, the isomerization of MTX after initial binding on the human enzyme, as evident in the nonlinearity of k obs versus MTX plot (Fig. S6D) , is completely absent from its binding to the E. coli DHFR (Fig. 7D inset) .
In conclusion, employing detailed inhibition kinetics, this study reports a set of novel and potent inhibitors of prokaryotic DHFR that have the potential to be developed as antibiotics for amelioration of conditions arising from bacterial infections. This, combined with the already reported antibacterial activity of AMPQD against two different strains of E. coli (multidrug-resistant E. coli and DH5a), a strain of methicillin-resistant S. aureus and a strain of vancomycin-resistant Enterococcus faecalis, makes this molecule a potential candidate for development as an antibiotic. Further, detailed kinetic assessment of the inhibition brought about by this molecule shows that it is competitive with respect to H 2 F and uncompetitive with respect to NADPH, with a preference of the inhibitor molecule for the NADPH-bound form of the enzyme. Furthermore, we show that although AMPQD is a slow-onset tight-binding inhibitor of E. coli DHFR, similar to MTX, PQD is merely a tight-binding inhibitor with no slow-onset behavior. This detailed kinetic characterization of the inhibitors, by means of providing additional insight on the structure-activity relationship, paves the way for development of better antifolates.
Experimental procedures
Reagents
All reagents and chemicals, unless mentioned otherwise, were of high quality and were procured from Sigma-Aldrich Co., (St. Louis, MO, USA), Amresco (Solon, OH, USA), or Fisher Scientific (Waltham, MA, USA). Escherichia coli dihydrofolate reductase was provided by E. Shakhnovich (Harvard University, Cambridge, MA, USA). The smallmolecule AMPQD (NSC309401), MTX (NSC740), PQD (NSC339578), methylbezoprim (NSC382035), pralatrexate (NSC754230), pemetrexed (NSC698037), 6,7-bis(4-aminophenyl) pteridine-2,4-diamine (NSC61642), 2,2 0 -iminostil- , resulting in a net decrease in the absorbance of NADPH at 340 nm. To understand the kinetics of E. coli DHFR and human DHFR, the rate of reduction of H 2 F to H 4 F was monitored by the decrease in absorbance at 340 nm for 100 s. The amount of product formed from the slope of initial velocity curves was computed using a molar extinction coefficient (e) of 6.2 9 10 3 M À1 Ácm À1 for b-NADPH at 340 nm [34] . The nonenzymatic hydrolysis of NADPH was normalized by monitoring the reaction in a double beam Hitachi U-2010 UV/vis spectrophotometer (Hitachi High Technologies America, Inc., San Jose, CA, USA) with an appropriate blank. All assays were carried out in the linear range of enzyme concentration. Assays were initiated with the addition of enzyme to the sample cuvette after zeroing the absorbance reading with respect to the reference cuvette. The initial velocities, where product formation was < 5%, were measured for reaction mixtures containing 100 mM Hepes pH 7.3 at room temperature (~22°C).
To determine the K m and V max for H 2 F and NADPH, the respective substrate was titrated at fixed saturating concentration of the other, and the resultant velocities were plotted against substrate concentration and fit to Eqn All measurements were performed in duplicate, and the error values indicated are standard deviations (SD). The concentration of E. coli DHFR used was 16.7 nM (see below for protocol of enzyme concentration estimation). Unless mentioned otherwise, all data were fit using nonlinear curve fitting subroutines of GraphPad PRISM, v. 4.0 (GraphPad Software, Inc., San Diego, CA, USA).
Velocity-titration curves for enzyme concentration estimation
To interpret inhibition data without errors (see below), an accurate estimate of catalytically active [E t ] is essential. Methods suggested by Williams et al. [33] , whereby velocity measurements after preincubation with a ligand (where enzyme-ligand complex is inactive and dissociates slowly), were followed to estimate the catalytically active total enzyme concentration. Briefly, 0.1 lg of E. coli DHFR and 0.16 lg of human DHFR were preincubated with various concentrations of MTX in 100 mM Hepes pH 7.3 and 60 lM NADPH for 300 s. The reaction was initiated with 50 lM H 2 F, and the resultant velocity was plotted as a function of MTX concentration (Fig. S7A-D) . The total concentration of the catalytically active enzyme is given by the intercept of the curve with the abscissa, which corresponds to 16.7 nM for of E. coli DHFR and 12.4 nM for human DHFR. The experiment was repeated with a preincubation time of 600 s, giving identical results. The concentration was also estimated employing a molar extinction coefficient of 33 
Inhibition kinetics
Various inhibitors were assessed for their inhibitory effect on the dihydrofolic acid reducing ability of E. coli DHFR and human DHFR. Initial inhibition was assessed in a reaction mixture containing 100 mM Hepes pH 7.3, 60 lM NADPH, 50 lM H 2 F and 1 mM of each inhibitor. The assay mix contained 16.7 nM of E. coli DHFR and 12.4 nM of human DHFR. Subsequently, both the potency of the inhibitor and its affinity for the enzyme were computed by experimental IC 50 determination and competition assays to determine its K i . IC 50 determination assays were carried out in 100 mM Hepes pH 7.3, 60 lM NADPH, 50 lM H 2 F and variable concentration of each inhibitor. The enzyme concentration was as specified above. The curves were fit to Eqn (2), where I is the inhibitor concentration, and y is the percentage activity.
Furthermore, K iapp values were computed from the IC 50 curves by fitting them to the quadratic Morrison equation (Eqn 3) for tight-binding inhibition. This equation accounts for tight binding by doing away with the assumption that the free concentration of inhibitor equals the total concentration.
where v i is the velocity in the presence of inhibitor, v 0 is the velocity in the absence of inhibitor, [E] T is the total enzyme, [I] T is the total inhibitor and K iapp is the apparent K i . Experimental K i value determinations were carried out by titrating the substrates H 2 F and NADPH, around their respective K m values, at various fixed concentrations of the inhibitors. The resulting [substrate] versus velocity curves were fit to the models of competitive inhibition (Eqn 4), noncompetitive inhibition (Eqn 5) and uncompetitive inhibition (Eqn 6) in order to discriminate between the different types of inhibition and to estimate the various inhibition constants (K i ).
Competitive:
Non-competitive:
Uncompetitive:
where v is the velocity of the reaction, V max is the maximum velocity, [S] is the substrate concentration and [I] is the inhibitor concentration. K m is the Michaelis-Menten constant, and K i is the inhibition constant. Visual assessment of the type of inhibition was undertaken by plotting the double reciprocal Lineweaver-Burk plot from experimental data points constituting the primary plot.
Progress curve analysis: slow-tight binding
The slow-onset inhibition of E. coli and human DHFR brought about by AMPQD, PQD and MTX was monitored by initiating the reaction with 16.7 nM of E. coli DHFR and 12.4 nM of human DHFR in assay mixtures containing 100 mM Hepes pH 7.3, 50 lM H 2 F, 60 lM NADPH and varying concentrations of inhibitor (0-25 lM). The reactions were allowed to proceed until the progress curve became linear, indicating that the enzyme has attained a steady state. To ensure that substrate depletion does not significantly affect the reaction rate, substrate concentrations greater than 10 times the respective K m values were used. Progress curves were analyzed as described previously [35] . Briefly, the resulting progress curves were fit to the integrated rate equation (Eqn 7) for slow binding inhibition by nonlinear regression analysis.
where, A t and A 0 are the absorbance at time t and time 0, k obs is the pseudo-first-order rate constant for approach to the steady state, whereas m i and m s correspond to the initial and final slopes of the progress curve. Values for m i , m s and k obs were obtained at each inhibitor concentration. Progress curves were approximately linear in the absence of added inhibitor. The values of k obs , v i and v s obtained from the fit to Eqn (7) were replotted to obtain the k off and k on for inhibitor binding for a classical single-step inhibition mechanism in which rapid reversible binding of the inhibitor occurs to the enzyme. Further, the patterns were also analyzed for possible two-step inhibition mechanism. In this case, which signifies a second slow step of isomerization after inhibitor binding to form the final enzyme-inhibitor complex, the following equation was used to fit the replot of k obs versus inhibitor to gauge its nonlinearity.
where k 4 and k -4 represent the forward and reverse rate constants for the isomerization step.
Thermal shift assay methodology
High-throughput thermal-shift assays were carried out following established guidelines [36, 37] . Briefly, thermal melt curves for proteins were obtained from samples aliquoted in 96-well plates using a RealPlex quantitative PCR instrument from Eppendorf (Hauppauge, NY, USA) with 5 9 Sypro orange dye as the fluorescent probe (Invitrogen, Carlsbad, CA, USA). (k ex is 465 nm and k em is 580 nm). A heating gradient of 1°CÁmin À1 from 25 to 75°C was used. Thermal melt experiments were carried out in 100 mM Hepes pH 7.3 and 150 mM NaCl with 20 lL total volume of the reaction mix. The concentration of AMPQD was varied from 0 to 500 nM at 5 lM of E. coli DHFR. All experiments were performed in duplicate, with the mean value considered for further analysis. The curves were fit to Boltzmann's equation (Eqn 9) for estimating the T m (melting temperature) from the observed intensity of fluorescence, I.
I ¼ I min þ ð½I max À I min =ð1 þ e ððTmÀTÞ=aÞ Þ ð 9Þ
I min and I max are the minimum and maximum intensities, and a is the slope of the curve at the transition midpoint temperate, T m [36] . Thermodynamic parameters were estimated as specified in the previous literature [15] .
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